MedCity News January 15, 2025
Marissa Plescia

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions.

The pressure against pharmacy benefit managers (PBMs) continues to build.

On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The commission voted 5-0 to release the report.

“The FTC staff’s...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Overprescribing and Polypharmacy: Arine CEO Talks The Hidden Dangers of Amazon’s Same-Day Prescription Delivery
Good Neighbor Pharmacy’s Tech Rx: Helping Independents Thrive in a Changing Market
How Clinical Pharmacist-Led Telehealth Models Are Transforming Diabetes Care
Q&A: Prepare for the Future of the AI in 2025

Share This Article